bluebird bio re-evaluates gene therapy strategy in ‘untenable’ European market
US biotech company says European payers have ‘not yet evolved their approach to gene therapy’
Read More
Tag: Bluebird Bio
bluebird bio’s sickle cell gene therapy granted MHRA ‘innovation passport’
Innovation passport designation scheme aims to reduce the time to market for promising treatments
Read More
Cross-industry alliance launches to increase awareness of cell and gene therapies in the UK
The Cell & Gene Collective is aiming to advocate for the adoption of next-generation medicine in the UK
Read More
FDA green light for BMS, bluebird bio’s CAR-T therapy Abecma in multiple myeloma
CAR-T therapy cleared for use in adults with relapsed or refractory multiple myeloma
Read More
bluebird bio’s beta-thalassaemia gene therapy rejected by NICE
NICE determined that there were uncertainties around the cost-effectiveness of the therapy
Read More
FDA refuse to file BMS/bluebird bio’s CAR-T therapy
The FDA did not request additional clinical or non-clinical data
Read More
CAR-T therapies shine at ASH
Janssen’s JNJ-4528 and BMS’ liso-cel show 100% response rates
Read More
Bluebird’s Zynteglo kicks off first Amsterdam CHMP recommendations
The European Medicines Agency’s CHMP positive opinions are sparse this time around.
Read More
- US study reveals interferon combinations cause lupus symptoms and affect treatment
- NIHR and TJBCM announce new funding initiative for novel brain tumour research
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
